Anticoagulation, Statins and “Arterial Thrombotic Sequalae after Covid-19: Mind the Gap”

[1]  M. Bailey,et al.  Lipid optimisation in lower extremity peripheral arterial disease. , 2021, Annals of vascular surgery.

[2]  M. P. Borrelli,et al.  Arterial Thrombotic Sequalae After Covid-19: Mind the Gap , 2021, Annals of Vascular Surgery.

[3]  M. Broncel,et al.  COVID-19: Direct and Indirect Mechanisms of Statins , 2021, International journal of molecular sciences.

[4]  D. Brodie,et al.  Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19 , 2021, Nature Communications.

[5]  H. Milionis,et al.  Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019? , 2020, Medical Hypotheses.

[6]  Ahmed M. Kamel,et al.  Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies , 2020, Reviews in medical virology.

[7]  H. Krumholz,et al.  Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies , 2020, Thrombosis Research.

[8]  G. Lippi,et al.  Statins and other drugs: Facing COVID-19 as a vascular disease , 2020, Pharmacological Research.

[9]  J. Phair,et al.  Acute thrombotic events as initial presentation of patients with COVID-19 infection , 2020, Journal of Vascular Surgery Cases and Innovative Techniques.

[10]  A. White,et al.  The Role of Anticoagulation in COVID-19-Induced Hypercoagulability , 2020, Current Cardiology Reports.

[11]  R. Bush,et al.  Acute limb ischemia in patients with COVID-19 pneumonia , 2020, Journal of Vascular Surgery.

[12]  M. Yaffe,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment , 2020, Journal of Thrombosis and Haemostasis.